Citizens Jmp Issues Pessimistic Forecast for Altimmune (NASDAQ:ALT) Stock Price

Altimmune (NASDAQ:ALT) had its price objective cut by Citizens Jmp from $14.00 to $11.00 in a research report issued to clients and investors on Thursday,Benzinga reports. The brokerage currently has a “market outperform” rating on the stock. Citizens Jmp’s price target suggests a potential upside of 285.96% from the company’s previous close.

A number of other brokerages also recently issued reports on ALT. HC Wainwright raised their price target on Altimmune from $12.00 to $25.00 and gave the stock a “buy” rating in a research report on Monday, March 16th. Barclays initiated coverage on Altimmune in a research report on Tuesday, January 27th. They issued an “overweight” rating and a $20.00 price target for the company. Truist Financial initiated coverage on Altimmune in a research report on Wednesday, March 18th. They issued a “buy” rating and a $12.00 price target for the company. Wall Street Zen downgraded Altimmune from a “hold” rating to a “sell” rating in a research report on Saturday, March 7th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Altimmune in a research report on Friday, March 27th. Seven analysts have rated the stock with a Buy rating, one has assigned a Hold rating and two have issued a Sell rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $17.50.

Altimmune Trading Down 2.4%

ALT stock opened at $2.85 on Thursday. The firm has a fifty day moving average price of $3.26 and a 200 day moving average price of $4.10. Altimmune has a fifty-two week low of $2.56 and a fifty-two week high of $7.73. The company has a debt-to-equity ratio of 0.12, a quick ratio of 18.55 and a current ratio of 29.56. The firm has a market cap of $370.79 million, a PE ratio of -3.06 and a beta of 0.18.

Altimmune (NASDAQ:ALT) last posted its earnings results on Wednesday, May 13th. The company reported ($0.18) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.25) by $0.07. Altimmune had a negative net margin of 214,860.98% and a negative return on equity of 42.57%. Sell-side analysts anticipate that Altimmune will post -0.96 earnings per share for the current fiscal year.

Insider Transactions at Altimmune

In related news, CEO Jerome Benedict Durso bought 20,000 shares of the business’s stock in a transaction on Friday, March 6th. The shares were bought at an average price of $3.54 per share, for a total transaction of $70,800.00. Following the completion of the purchase, the chief executive officer directly owned 32,500 shares of the company’s stock, valued at approximately $115,050. This trade represents a 160.00% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 1.60% of the stock is owned by company insiders.

Institutional Investors Weigh In On Altimmune

Large investors have recently modified their holdings of the business. Arax Advisory Partners boosted its position in Altimmune by 99.7% in the fourth quarter. Arax Advisory Partners now owns 8,165 shares of the company’s stock valued at $29,000 after buying an additional 4,076 shares during the last quarter. SBI Securities Co. Ltd. boosted its position in Altimmune by 27.9% in the fourth quarter. SBI Securities Co. Ltd. now owns 8,837 shares of the company’s stock valued at $32,000 after buying an additional 1,928 shares during the last quarter. Quadrature Capital Ltd purchased a new stake in Altimmune in the fourth quarter valued at approximately $36,000. Victory Capital Management Inc. purchased a new stake in Altimmune in the third quarter valued at approximately $38,000. Finally, CreativeOne Wealth LLC purchased a new stake in Altimmune in the fourth quarter valued at approximately $38,000. Hedge funds and other institutional investors own 78.05% of the company’s stock.

About Altimmune

Altimmune, Inc is a clinical-stage biopharmaceutical company headquartered in Gaithersburg, Maryland, dedicated to the development of vaccines and immunotherapeutics. The company leverages proprietary technology platforms to create intranasal vaccine candidates and novel therapies targeting liver diseases and metabolic disorders. Altimmune’s approach emphasizes the stimulation of both systemic and mucosal immune responses to address unmet medical needs in infectious and chronic conditions.

Among its lead programs, NasoVAX is an investigational intranasal influenza vaccine designed to provide broad, long-lasting protection through a single, non-invasive dose.